193 related articles for article (PubMed ID: 29669775)
1. A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab.
Shaikh H; Daboul N; Albrethsen M; Fazal S
BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29669775
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin.
Algaze SD; Park W; Harrington TJ; Mudad R
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29523604
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
4. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-associated autoimmune haemolytic anaemia.
Johnstone P; Khan O
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31653618
[TBL] [Abstract][Full Text] [Related]
7. The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.
Ochi M; Miyamoto S; Terada Y; Furuhata Y; Awano N; Izumo T; Ikushima S; Bae Y; Kumasaka T; Kunito H
Intern Med; 2018 Jun; 57(12):1773-1777. PubMed ID: 29434118
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient.
Abe J; Sato T; Tanaka R; Okazaki T; Takahashi S
Am J Case Rep; 2016 Nov; 17():880-882. PubMed ID: 27893699
[TBL] [Abstract][Full Text] [Related]
9. Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
Kudo F; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Ota H; Yabe H; Demitsu T; Hagiwara K; Koyama N; Koyama S
Intern Med; 2018 Aug; 57(15):2217-2221. PubMed ID: 29526968
[TBL] [Abstract][Full Text] [Related]
10. Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.
Pluchart H; Pinsolle J; Cohen J; Ferretti GR; Bedouch P; Giaj Levra M; Toffart AC; Moro-Sibilot D
J Med Case Rep; 2017 Jul; 11(1):183. PubMed ID: 28679408
[TBL] [Abstract][Full Text] [Related]
11. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Yasuda Y; Urata Y; Tohnai R; Ito S; Kawa Y; Kono Y; Hattori Y; Tsuda M; Sakuma T; Negoro S; Satouchi M
Intern Med; 2018 May; 57(9):1269-1272. PubMed ID: 29279482
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
14. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
[TBL] [Abstract][Full Text] [Related]
15. Treatment of childhood autoimmune haemolytic anaemia with rituximab.
Quartier P; Brethon B; Philippet P; Landman-Parker J; Le Deist F; Fischer A
Lancet; 2001 Nov; 358(9292):1511-3. PubMed ID: 11705566
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis.
Williams H; Aitchison R
BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31811095
[TBL] [Abstract][Full Text] [Related]
17. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
18. An Autoimmune Haemolytic Anaemia Secondary to Ipilimumab Treatment.
Ramos B; Gastal G; Rovere RK
Klin Onkol; 2017; 30(2):128-130. PubMed ID: 28397508
[TBL] [Abstract][Full Text] [Related]
19. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
20. Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.
Catania C; Passaro A; Rocco EG; Spitaleri G; Barberis M; Noberasco C; Signore ED; Travaini L; de Marinis F
Clin Lung Cancer; 2016 Sep; 17(5):e179-e183. PubMed ID: 27349506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
